| Project Detail |
We learned from the pandemic that air quality is essential for people’s health. Current technologies did not effectively manage infectious diseases propagated by aerosol suspensions of pathogens, leading to the need for social distancing and dramatically impacting the economy and people’s mental health. The challenge is not only cleaning the space but keeping people safe and free from microorganisms’ exposure without harming them with harsh chemicals.
Delox AIR solution will change the paradigm of bio-decontamination of airborne pathogens in occupied spaces, a disruptive factor in the market. Based on our proprietary dryVHP, Delox AIR can kill microorganisms in the air with 99.99% efficacy, ensuring 100% human safety and consuming up to 20% less energy than current systems. Delox AIR can be readily integrated into any HVAC systems for continuous air purification.
Delox AIR is part of the air purification market. We are targeting the commercial applications that capture the largest market (˜70% in 2021), accounting for €15.0 B by 2030. We will first target settings characterised by high occupancy density, presence of vulnerable individuals, and elevated risk of pathogen spread, such as nursing homes and hospitals, office spaces and educational and governmental buildings.
Our business model (B2B) is based on indirect sales through distributors already working in the sector that will easily reach HVAC consultants/contractors (customer) designing and delivering a turnkey HVAC system for the end-user.
We request EIC funding to complete the development of our system and validate it in three different types of closed environments. Our solution addresses the EIC Challenge of “Aerosol Decontamination for Pandemic Management”, satisfying the unmet need of facilitating social interaction and preventing disease spread. |
